Eledon Pharmaceuticals (ELDN) Liabilities and Shareholders Equity (2016 - 2017)
Historic Liabilities and Shareholders Equity for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q3 2017 value amounting to $23.0 million.
- Eledon Pharmaceuticals' Liabilities and Shareholders Equity fell 3731.38% to $23.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $76.9 million, marking a year-over-year decrease of 6325.66%. This contributed to the annual value of $1.2 million for FY2016, which is 9824.05% down from last year.
- Latest data reveals that Eledon Pharmaceuticals reported Liabilities and Shareholders Equity of $23.0 million as of Q3 2017, which was down 3731.38% from $26.8 million recorded in Q2 2017.
- Eledon Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $107.7 million during Q4 2014, with a 5-year trough of $1.2 million in Q4 2016.
- Over the past 5 years, Eledon Pharmaceuticals' median Liabilities and Shareholders Equity value was $52.3 million (recorded in 2016), while the average stood at $56.8 million.
- In the last 5 years, Eledon Pharmaceuticals' Liabilities and Shareholders Equity surged by 23370.71% in 2014 and then tumbled by 9824.05% in 2016.
- Quarter analysis of 5 years shows Eledon Pharmaceuticals' Liabilities and Shareholders Equity stood at $32.3 million in 2013, then skyrocketed by 233.71% to $107.7 million in 2014, then tumbled by 36.91% to $68.0 million in 2015, then crashed by 98.24% to $1.2 million in 2016, then surged by 1824.67% to $23.0 million in 2017.
- Its last three reported values are $23.0 million in Q3 2017, $26.8 million for Q2 2017, and $25.8 million during Q1 2017.